

Raccolta informazioni su Gruppi di Ricerca- DiSCOG

CAPOGRUPPO

Nominativo	Simone Mocellin
Ruolo Universitario	Ricercatore
SSD	MED/18
Ruolo ospedaliero (se presente)	
Sezione di appartenenza	Clinica Chirurgica 1 (Direttore Prof. D. Nitti)
Unità Operativa Semplice (se presente)	
Unità Operativa Complessa	

LINEE DI RICERCA (solo linee di ricerca attuali; se presenti piu' linee di ricerca indiarle con un numero e fare riferimento al numero per tutte le informazioni sottostanti, quando appropriato)

- 1) Gastrointestinal cancer: clinical trials, prognostic and predictive biomarkers, surgery, locoregional treatments, adjuvant therapy
- 2) Melanoma & Soft tissue sarcomas: clinical trials, prognostic and predictive biomarkers, surgery, locoregional treatments, sentinel lymph node, adjuvant therapy
- 3) Breast cancer: clinical trials, prognostic and predictive biomarkers, surgery, sentinel lymph node, adjuvant therapy
- 4) Evidence-based medicine: meta-analysis of randomized trials, molecular epidemiology, diagnostic test of accuracy; analysis of large databases from population-based studies.
- 5) Cancer chemoresistance: molecular mechanisms and therapeutic strategies
- 6) Cancer biotherapy: immunotherapy and cytokines

AFFERENTI AL GRUPPO DI RICERCA

1) PERSONALE UNIVERSITARIO (PROFESSORI E RICERCATORI)

Nominativo	Ruolo (SSD)	Dipartimento di afferenza

2) PERSONALE NON STRUTTURATO (DOTTORANDI, SPECIALIZZANDI, ASSEGNISTI, BORSISTI)

Nominativo	Ruolo ** per gli specializzandi e dottorandi specificare la scuola di appartenenza	Dipartimento di afferenza
Sandro Pasquali	Specializzando (Chirurgia)	DiSCOG
Daunia Verdi	Specializzanda (Chirurgia)	DiSCOG
Francesco Russano	Dottorando (Oncologia)	DiSCOG
Andrea Lana	Dottorando (Oncologia)	DiSCOG

3) PERSONALE TECNICO DI LABORATORIO STRUTTURATO

Nominativo	Livello	Dipartimento di afferenza
Clara Benna		DiSCOG

4) **PERSONALE DI RICERCA APPARTENENTE AD ALTRE AMMINISTRAZIONI (IOV, AZIENDA OSPEDALIERA, VIMM, ETC)**

Nominativo	Ruolo	Ente di appartenenza
Pierluigi Pilati	Dirigente medico	Azienda Ospedaliera PD
Alberto Marchet	Dirigente medico	Azienda Ospedaliera PD

COLLABORAZIONI NAZIONALI E INTERNAZIONALI SOSTENUTI DA: PROGETTI DI RICERCA/PUBBLICAZIONI/SCAMBI DI PERSONALE

(ultimi 5 anni, sostanziate da piu' pubblicazioni e/o progetti di ricerca in comune)

Sydney Melanoma Unit (Sydney, Australia) (pubblicazioni, scambi di personale [Dr. S. Pasquali])

Cochrane Colorectal Cancer group (Copenhagen, Denmark) (pubblicazioni)

PARTECIPAZIONE A PROGETTI INTERNAZIONALI (ultimi 5 anni; indicare per ogni linea di ricerca)

Melanoma Molecular Map Project (www.mmmp.org)

FINANZIAMENTI (ultimi 5 anni; indicare per ogni linea di ricerca)

PROGETTO DI ATENE0 2008-2011 (Ruolo prognostico delle cellule tumorali circolanti nei pazienti con metastasi epatiche resecabili da carcinoma coloretale)

PUBBLICAZIONI (ultimi 5 anni; solo pubblicazioni ISI e non abstract; indicare per ogni linea di ricerca)

1) Gastrointestinal cancer: clinical trials, prognostic and predictive biomarkers, surgery, locoregional treatments, adjuvant therapy

PILATI P, MOCELLIN S, BERTAZZA L, GALDI F, BRIARAVA M, MAMMANO E, TESSARI E, ZAVAGNO G, NITTI D. PROGNOSTIC VALUE OF PUTATIVE CIRCULATING CANCER STEM CELLS IN PATIENTS UNDERGOING HEPATIC RESECTION FOR COLORECTAL LIVER METASTASIS. ANN SURG ONCOL. 2012 FEB;19(2):402-8.

MARCHET A, MOCELLIN S, AMBROSI A, MORGAGNI P, VITTIMBERGA G, ROVIELLO F, MARRELLI D, DE MANZONI G, MINICOZZI A, CONIGLIO A, TIBERIO G, PACELLI F, ROSA F, NITTI D.

VALIDATION OF THE NEW AJCC TNM STAGING SYSTEM FOR GASTRIC CANCER IN A LARGE COHORT OF PATIENTS (N = 2,155): FOCUS ON THE T CATEGORY.

EUR J SURG ONCOL. 2011 SEP;37(9):779-85.

BERTAZZA L, MOCELLIN S, MARCHET A, PILATI P, GABRIELI J, SCALERTA R, NITTI D.

SURVIVIN GENE LEVELS IN THE PERIPHERAL BLOOD OF PATIENTS WITH GASTRIC CANCER INDEPENDENTLY PREDICT SURVIVAL. J TRANSL MED. 2009 DEC 22;7:111.

PILATI P, MAMMANO E, MOCELLIN S, TESSARI E, LISE M, NITTI D.

HEPATIC ARTERIAL INFUSION FOR UNRESECTABLE COLORECTAL LIVER METASTASES COMBINED OR NOT WITH SYSTEMIC CHEMOTHERAPY.

ANTICANCER RES. 2009 OCT;29(10):4139-44.

MAMMANO E, PILATI P, TESSARI E, COSCI M, MOCELLIN S, NITTI D.

[ADJUVANT CHEMOTHERAPY AFTER RADICAL LIVER RESECTION IN THE TREATMENT OF METASTASES FROM COLORECTAL CARCINOMA].

MINERVA CHIR. 2009 OCT;64(5):457-63.

NITTI D, MARCHET A, MOCELLIN S, ROSSI GM, AMBROSI A, MENCARELLI R.
PROGNOSTIC VALUE OF SUBCLASSIFICATION OF T2 TUMOURS IN PATIENTS WITH GASTRIC CANCER.
BR J SURG. 2009 APR;96(4):398-404.

NITTI D, MOCELLIN S, MARCHET A, PILATI P, LISE M.
RECENT ADVANCES IN CONVENTIONAL AND MOLECULAR PROGNOSTIC FACTORS FOR GASTRIC CARCINOMA.
SURG ONCOL CLIN N AM. 2008 JUL;17(3):467-83, vii.

MARCHET A, MOCELLIN S, AMBROSI A, DE MANZONI G, DI LEO A, MARRELLI D, ROVIELLO F, MORGAGNI P, SARAGONI L, NATALINI G, DE SANTIS F, BAIOCCHI L, CONIGLIO A, NITTI D; ITALIAN RESEARCH GROUP FOR GASTRIC CANCER STUDY (GIRCG).
THE PROGNOSTIC VALUE OF N-RATIO IN PATIENTS WITH GASTRIC CANCER: VALIDATION IN A LARGE, MULTICENTER SERIES.
EUR J SURG ONCOL. 2008 FEB;34(2):159-65.

2) Melanoma & Soft tissue sarcomas: clinical trials, prognostic and predictive biomarkers, surgery, locoregional treatments, sentinel lymph node, adjuvant therapy

ROSSI CR, VECCHIATO A, MASTRANGELO G, MONTESCO MC, RUSSANO F, MOCELLIN S, PASQUALI S, SCARZELLO G, BASSO U, FRASSON A, PILATI P, NITTI D, LURKIN A, RAY-COQUARD I.
ADHERENCE TO TREATMENT GUIDELINES FOR PRIMARY SARCOMAS AFFECTS PATIENT SURVIVAL: A SIDE STUDY OF THE EUROPEAN CONNECTIVE TISSUE CANCER NETWORK (CONTICANET).
ANN ONCOL. 2013 FEB 27. [EPUB AHEAD OF PRINT] PUBMED PMID:23446092.

PASQUALI S, VAN DER PLOEG AP, MOCELLIN S, STRETCH JR, THOMPSON JF, SCOLYER RA.
LYMPHATIC BIOMARKERS IN PRIMARY MELANOMAS AS PREDICTORS OF REGIONAL LYMPH NODE METASTASIS AND PATIENT OUTCOMES.
PIGMENT CELL MELANOMA RES. 2013 JAN 8. DOI: 10.1111/PCMR.12064. [EPUB AHEAD OF PRINT] PUBMED PMID: 23298266.

VECCHIATO A, PASQUALI S, MENIN C, MONTESCO MC, ALAIBAC M, MOCELLIN S, CAMPANA LG, NITTI D, ROSSI CR.
HISTOPATHOLOGICAL CHARACTERISTICS OF SUBSEQUENT MELANOMAS IN PATIENTS WITH MULTIPLE PRIMARY MELANOMAS.
J EUR ACAD DERMATOL VENEREOL. 2012 DEC 6. DOI: 10.1111/JDV.12055. [EPUB AHEAD OF PRINT] PUBMED PMID: 23216522.

CAMPANA LG, VALPIONE S, MOCELLIN S, SUNDARARAJAN R, GRANZIERA E, SARTORE L, CHIARION-SILENI V, ROSSI CR.
ELECTROCHEMOTHERAPY FOR DISSEMINATED SUPERFICIAL METASTASES FROM MALIGNANT MELANOMA.
BR J SURG. 2012 JUN;99(6):821-30.

PASQUALI S, MOCELLIN S, CAMPANA LG, VECCHIATO A, BONANDINI E, MONTESCO MC, SANTARCANGELO S, ZAVAGNO G, NITTI D, ROSSI CR.
MAXIMIZING THE CLINICAL USEFULNESS OF A NOMOGRAM TO SELECT PATIENTS CANDIDATE TO SENTINEL NODE BIOPSY FOR CUTANEOUS MELANOMA.
EUR J SURG ONCOL. 2011 AUG;37(8):675-80.

ROSSI CR, PASQUALI S, MOCELLIN S, VECCHIATO A, CAMPANA LG, PILATI P, ZANON A, NITTI D.
LONG-TERM RESULTS OF MELPHALAN-BASED ISOLATED LIMB PERFUSION WITH OR WITHOUT LOW-DOSE TNF FOR IN-TRANSIT MELANOMA METASTASES.
ANN SURG ONCOL. 2010 NOV;17(11):3000-7.

MOCELLIN S, THOMPSON JF, PASQUALI S, MONTESCO MC, PILATI P, NITTI D, SAW RP, SCOLYER RA, STRETCH JR, ROSSI CR.
SENTINEL NODE STATUS PREDICTION BY FOUR STATISTICAL MODELS: RESULTS FROM A LARGE BI-INSTITUTIONAL SERIES (N = 1132).
ANN SURG. 2009 DEC;250(6):964-9.

TESTORI A, DE SALVO GL, MONTESCO MC, TRIFIRÒ G, MOCELLIN S, LANDI G, MACRIPÒ G, CARCOFORO P, RICOTTI G, GIUDICE G, PICCIOTTO F, DONNER D, DI FILIPPO F, SOTELDO J, CASARA D, SCHIAVON M, VECCHIATO A, PASQUALI S, BALDINI F, MAZZAROL G, ROSSI CR; ITALIAN MELANOMA INTERGROUP.
CLINICAL CONSIDERATIONS ON SENTINEL NODE BIOPSY IN MELANOMA FROM AN ITALIAN MULTICENTRIC STUDY ON 1,313 PATIENTS (SOLISM-IMI).

ANN SURG ONCOL. 2009 JUL;16(7):2018-27.

CAMPANA LG, MOCELLIN S, BASSO M, PUCETTI O, DE SALVO GL, CHIARION-SILENI V, VECCHIATO A, CORTI L, ROSSI CR, NITTI D.

BLEOMYCIN-BASED ELECTROCHEMOTHERAPY: CLINICAL OUTCOME FROM A SINGLE INSTITUTION'S EXPERIENCE WITH 52 PATIENTS.
ANN SURG ONCOL. 2009 JAN;16(1):191-9.

ROSSI CR, PASQUALI S, MOCELLIN S.

ACTUAL FALSE-NEGATIVE RATE PROMPTS THE ROUTINE USE OF ULTRASOUND SCAN BEFORE AND AFTER SENTINEL NODE BIOPSY IN MELANOMA.

ANN SURG ONCOL. 2008 OCT;15(10):2976-7.

MOCELLIN S, ROSSI CR.

THE MELANOMA MOLECULAR MAP PROJECT.

MELANOMA RES. 2008 JUN;18(3):163-5.

ROSSI CR, RUSSANO F, MOCELLIN S, CHIARION-SILENI V, FOLETTO M, PILATI P, CAMPANA LG, ZANON A, PICCHI GF, LISE M, NITTI D.

TNF-BASED ISOLATED LIMB PERFUSION FOLLOWED BY CONSOLIDATION BIOTHERAPY WITH SYSTEMIC LOW-DOSE INTERFERON ALPHA 2B IN PATIENTS WITH IN-TRANSIT MELANOMA METASTASES: A PILOT TRIAL.

ANN SURG ONCOL. 2008 APR;15(4):1218-23.

ROSSI CR, DE SALVO GL, BONANDINI E, MOCELLIN S, FOLETTO M, PASQUALI S, PILATI P, LISE M, NITTI D, RIZZO E, MONTESCO MC.

FACTORS PREDICTIVE OF NONSENTINEL LYMPH NODE INVOLVEMENT AND CLINICAL OUTCOME IN MELANOMA PATIENTS WITH METASTATIC SENTINEL LYMPH NODE.

ANN SURG ONCOL. 2008 APR;15(4):1202-10.

ROSSI CR, MOCELLIN S, PASQUALI S, PILATI P, NITTI D.

N-RATIO: A NOVEL INDEPENDENT PROGNOSTIC FACTOR FOR PATIENTS WITH STAGE-III CUTANEOUS MELANOMA.

ANN SURG ONCOL. 2008 JAN;15(1):310-5.

3) Breast cancer: clinical trials, prognostic and predictive biomarkers, surgery, sentinel lymph node, adjuvant therapy

CAMPANA LG, VALPIONE S, FALCI C, MOCELLIN S, BASSO M, CORTI L, BALESTRIERI N, MARCHET A, ROSSI CR.

THE ACTIVITY AND SAFETY OF ELECTROCHEMOTHERAPY IN PERSISTENT CHEST WALL RECURRENCE FROM BREAST CANCER AFTER MASTECTOMY: A PHASE-II STUDY.

BREAST CANCER RES TREAT. 2012 AUG;134(3):1169-78.

ARTIOLI G, MOCELLIN S, BORGATO L, CAPPETTA A, BOZZA F, ZAVAGNO G, ZOVATO S, MARCHET A, PASTORELLI D. PHASE II STUDY OF NEOADJUVANT GEMCITABINE, PEGYLATED LIPOSOMAL DOXORUBICIN, AND DOCETAXEL IN LOCALLY ADVANCED BREAST CANCER.

ANTICANCER RES. 2010 SEP;30(9):3817-21.

ZAVAGNO G, DONÀ M, ORVIETO E, MOCELLIN S, PASQUALI S, GOLDIN E, MELE ML, BELARDINELLI V, NITTI D. SEPARATE CAVITY MARGINS EXCISION AS A COMPLEMENT TO CONSERVATIVE BREAST CANCER SURGERY.

EUR J SURG ONCOL. 2010 JUL;36(7):632-8.

ARTIOLI G, BORGATO L, CAPPETTA A, WABERSICH J, MOCELLIN S, DALLA PALMA M, NICOLETTO O.

OVERALL SURVIVAL IN BRCA-ASSOCIATED OVARIAN CANCER: CASE-CONTROL STUDY OF AN ITALIAN SERIES.

EUR J GYNAECOL ONCOL. 2010;31(6):658-61.

ZAVAGNO G, GOLDIN E, MENCARELLI R, CAPITANIO G, DEL BIANCO P, MARCONATO R, MOCELLIN S, MARCONATO G, BELARDINELLI V, MARCON F, NITTI D.

ROLE OF RESECTION MARGINS IN PATIENTS TREATED WITH BREAST CONSERVATION SURGERY.

CANCER. 2008 MAY 1;112(9):1923-31.

4) Evidence-based medicine: meta-analysis of randomized trials, molecular epidemiology, diagnostic test of accuracy; analysis of large databases from population-based studies.

MOCELLIN S, VERDI D, POOLEY KA, LANDI MT, EGAN KM, BAIRD DM, PRESCOTT J, DE VIVO I, NITTI D. TELOMERASE REVERSE TRANSCRIPTASE LOCUS POLYMORPHISMS AND CANCER RISK: A FIELD SYNOPSIS AND META-ANALYSIS. J NATL CANCER INST. 2012 JUN 6;104(11):840-54.

PETERSEN SH, HARLING H, KIRKEBY LT, WILLE-JØRGENSEN P, MOCELLIN S. POSTOPERATIVE ADJUVANT CHEMOTHERAPY IN RECTAL CANCER OPERATED FOR CURE. COCHRANE DATABASE SYST REV. 2012 MAR 14;3:CD004078.

NOVARA G, FICARRA V, MOCELLIN S, AHLERING TE, CARROLL PR, GRAEFEN M, GUAZZONI G, MENON M, PATEL VR, SHARIAT SF, TEWARI AK, VAN POPPEL H, ZATTONI F, MONTORSI F, MOTTRIE A, ROSEN RC, WILSON TG. SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES REPORTING ONCOLOGIC OUTCOME AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY. EUR UROL. 2012 SEP;62(3):382-404.

MOCELLIN S, MARCHET A, NITTI D. EUS FOR THE STAGING OF GASTRIC CANCER: A META-ANALYSIS. GASTROINTEST ENDOSC. 2011 JUN;73(6):1122-34.

MOCELLIN S, PASQUALI S, NITTI D. THE IMPACT OF SURGERY ON SURVIVAL OF PATIENTS WITH CUTANEOUS MELANOMA: REVISITING THE ROLE OF PRIMARY TUMOR EXCISION MARGINS. ANN SURG. 2011 FEB;253(2):238-43.

MOCELLIN S, NITTI D. CUTANEOUS MELANOMA IN SITU: TRANSLATIONAL EVIDENCE FROM A LARGE POPULATION-BASED STUDY. ONCOLOGIST. 2011;16(6):896-903.

MOCELLIN S, PASQUALI S, ROSSI CR, NITTI D. VALIDATION OF THE PROGNOSTIC VALUE OF LYMPH NODE RATIO IN PATIENTS WITH CUTANEOUS MELANOMA: A POPULATION-BASED STUDY OF 8,177 CASES. SURGERY. 2011 JUL;150(1):83-90.

MOCELLIN S, PASQUALI S, ROSSI CR, NITTI D. INTERFERON ALPHA ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MELANOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. J NATL CANCER INST. 2010 APR 7;102(7):493-501.

PASQUALI S, MOCELLIN S, CAMPANA LG, BONANDINI E, MONTESCO MC, TREGNAGHI A, DEL FIORE P, NITTI D, ROSSI CR. EARLY (SENTINEL LYMPH NODE BIOPSY-GUIDED) VERSUS DELAYED LYMPHADENECTOMY IN MELANOMA PATIENTS WITH LYMPH NODE METASTASES : PERSONAL EXPERIENCE AND LITERATURE META-ANALYSIS. CANCER. 2010 MAR 1;116(5):1201-9.

MOCELLIN S, VERDI D, NITTI D. DNA REPAIR GENE POLYMORPHISMS AND RISK OF CUTANEOUS MELANOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. CARCINOGENESIS. 2009 OCT;30(10):1735-43.

MOCELLIN S, PASQUALI S, NITTI D. FLUOROPYRIMIDINE-HAI (HEPATIC ARTERIAL INFUSION) VERSUS SYSTEMIC CHEMOTHERAPY (SCT) FOR UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER. COCHRANE DATABASE SYST REV. 2009 JUL 8;(3):CD007823.

MOCELLIN S, ZAVAGNO G, NITTI D. THE PROGNOSTIC VALUE OF SERUM S100B IN PATIENTS WITH CUTANEOUS MELANOMA: A META-ANALYSIS. INT J CANCER. 2008 NOV 15;123(10):2370-6.

MOCELLIN S, NITTI D.

VITAMIN D RECEPTOR POLYMORPHISMS AND THE RISK OF CUTANEOUS MELANOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS.
CANCER. 2008 NOV 1;113(9):2398-407.

5) Cancer biology and chemoresistance: molecular mechanisms and therapeutic strategies

PILATI P, NITTI D, MOCELLIN S.

CANCER RESISTANCE TO TYPE II TOPOISOMERASE INHIBITORS.
CURR MED CHEM. 2012;19(23):3900-6.

MOCELLIN S, POOLEY KA, NITTI D.

TELOMERASE AND THE SEARCH FOR THE END OF CANCER.
TRENDS MOL MED. 2013 FEB;19(2):125-33.

MOCELLIN S, BERTAZZA L, BENNA C, PILATI P.

CIRCUMVENTING MELANOMA CHEMORESISTANCE BY TARGETING DNA REPAIR.
CURR MED CHEM. 2012;19(23):3893-9.

MOCELLIN S.

EDITORIAL: CANCER CHEMORESISTANCE AND DNA REPAIR.
CURR MED CHEM. 2012;19(23):3857

MOCELLIN S.

VITAMIN D AND CANCER: DECIPHERING THE TRUTH.
BIOCHIM BIOPHYS ACTA. 2011 DEC;1816(2):172-8.

MOCELLIN S, SHRAGER J, SCOLYER R, PASQUALI S, VERDI D, MARINCOLA FM, BRIARAVA M, GOBBEL R, ROSSI C, NITTI D.

TARGETED THERAPY DATABASE (TTD): A MODEL TO MATCH PATIENT'S MOLECULAR PROFILE WITH CURRENT KNOWLEDGE ON
CANCER BIOLOGY.
PLOS ONE. 2010 AUG 10;5(8):E11965.

MOCELLIN S.

NITRIC OXIDE: CANCER TARGET OR ANTICANCER AGENT?
CURR CANCER DRUG TARGETS. 2009 MAR;9(2):214-36.

MOCELLIN S, PASQUALI S, PILATI P.

ONCOMIRS: FROM TUMOR BIOLOGY TO MOLECULARLY TARGETED ANTICANCER STRATEGIES.
MINI REV MED CHEM. 2009 JAN;9(1):70-80.

BERTAZZA L, MOCELLIN S, NITTI D.

CIRCULATING TUMOR CELLS IN SOLID CANCER: TUMOR MARKER OF CLINICAL RELEVANCE?
CURR ONCOL REP. 2008 MAR;10(2):137-46.

6) Cancer biotherapy: immunotherapy and cytokines

MOCELLIN S, BENNA C, PILATI P.

COINHIBITORY MOLECULES IN CANCER BIOLOGY AND THERAPY.
CYTOKINE GROWTH FACTOR REV. 2013 APR;24(2):147-61.

MOCELLIN S.

PEPTIDES IN MELANOMA THERAPY.
CURR PHARM DES. 2012;18(6):820-31.

MOCELLIN S.

CYTOKINES AS ANTI-CANCER AGENTS RATIONAL, RESULTS AND PERSPECTIVES.
CURR MED CHEM. 2010;17(29):3296.

PASQUALI S, MOCELLIN S.

THE ANTICANCER FACE OF INTERFERON ALPHA (IFN-ALPHA): FROM BIOLOGY TO CLINICAL RESULTS, WITH A FOCUS ON MELANOMA.
CURR MED CHEM. 2010;17(29):3327-36.

BERTAZZA L, MOCELLIN S.

THE DUAL ROLE OF TUMOR NECROSIS FACTOR (TNF) IN CANCER BIOLOGY.
CURR MED CHEM. 2010;17(29):3337-3352.

MOCELLIN S.

TARGETING DEATH RECEPTORS TO FIGHT CANCER: FROM BIOLOGICAL RATIONAL TO CLINICAL IMPLEMENTATION.
CURR MED CHEM. 2010;17(25):2713-28.

MOCELLIN S.

METABOLIC IMMUNE RESTRAINTS: IMPLICATIONS FOR ANTICANCER VACCINES.
CURR PHARM DES. 2010 JAN;16(3):277-91.

MOCELLIN S.

NEW GENERATION CANCER VACCINES: FROM TUMOR IMMUNOLOGY TO CLINICAL APPLICATIONS.
CURR PHARM DES. 2010 JAN;16(3):253-4.

MANDRUZZATO S, SOLITO S, FALISI E, FRANCESCATO S, CHIARION-SILENI V, MOCELLIN S, ZANON A, ROSSI CR, NITTI D, BRONTE V, ZANOVELLO P.

IL4RALPHA+ MYELOID-DERIVED SUPPRESSOR CELL EXPANSION IN CANCER PATIENTS.
J IMMUNOL. 2009 MAY 15;182(10):6562-8.

MOCELLIN S, PILATI P, NITTI D.

PEPTIDE-BASED ANTICANCER VACCINES: RECENT ADVANCES AND FUTURE PERSPECTIVES.
CURR MED CHEM. 2009;16(36):4779-96.

BRONTE V, MOCELLIN S.

SUPPRESSIVE INFLUENCES IN THE IMMUNE RESPONSE TO CANCER.
J IMMUNOTHER. 2009 JAN;32(1):1-11.

MOCELLIN S, NITTI D.

THERAPEUTICS TARGETING TUMOR IMMUNE ESCAPE: TOWARDS THE DEVELOPMENT OF NEW GENERATION ANTICANCER VACCINES.
MED RES REV. 2008 MAY;28(3):413-44.

PILATI P, ROSSI CR, MOCELLIN S.

STRATEGIES TO ENHANCE THE ANTICANCER POTENTIAL OF TNF.
FRONT BIOSCI. 2008 JAN 1;13:3181-93.

MOCELLIN S, NITTI D.

TNF AND CANCER: THE TWO SIDES OF THE COIN.
FRONT BIOSCI. 2008 JAN 1;13:2774-83.

BERTAZZA L, MOCELLIN S.

TUMOR NECROSIS FACTOR (TNF) BIOLOGY AND CELL DEATH.
FRONT BIOSCI. 2008 JAN 1;13:2736-43.

TECNOLOGIA, METODICHE, COMPETENZE DISPONIBILI PER POSSIBILI FUTURE COLLABORAZIONI

Laboratorio: biologia molecolare e cellulare, RNA interference, test di citotossicità in vitro (chemioresistenza), test molecolari (e.g. PCR quantitativa real time, anche per la ricerca di cellule tumorali circolanti) per biomarcatori prognostici e predittivi.

Disegno, conduzione e analisi dei risultati di trials clinici.

Gestione e analisi di grandi database ($>10^6$ casi).

Biostatistica avanzata, con particolare riferimento a meta-analisi (terapeutiche, prognostiche, diagnostiche e di epidemiologia molecolare), analisi di sopravvivenza, modelli predittivi.